Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Monopar Therapeutics from a "sell" to a "strong sell", even though MarketBeat's aggregate shows an overall analyst consensus of "Buy" with an average price target of $107.
• Shares opened at $56.08 and were trading down about 3.2%; the company has a market cap of $375M, reported an EPS miss (‑$0.61 vs. estimate ‑$0.51), and analysts forecast a FY EPS of ‑1.65 with a 12‑month range of $28.40–$105.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was downgraded by analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday.

MNPR has been the subject of several other reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Chardan Capital reaffirmed a "buy" rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Morgan Stanley assumed coverage on Monopar Therapeutics in a research report on Friday, January 9th. They set an "overweight" rating and a $115.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Finally, BTIG Research reaffirmed a "buy" rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $107.00.

Monopar Therapeutics Trading Down 3.2%

NASDAQ MNPR opened at $56.08 on Friday. The firm has a market capitalization of $375.18 million, a P/E ratio of -30.81 and a beta of 1.64. The business has a fifty day simple moving average of $56.79 and a 200 day simple moving average of $70.55. Monopar Therapeutics has a 12 month low of $28.40 and a 12 month high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10). As a group, sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP purchased a new position in Monopar Therapeutics during the 3rd quarter valued at about $18,904,000. Siren L.L.C. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $13,863,000. Deerfield Management Company L.P. purchased a new position in Monopar Therapeutics during the 3rd quarter valued at about $13,048,000. RA Capital Management L.P. grew its holdings in Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock valued at $43,569,000 after buying an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC purchased a new position in Monopar Therapeutics during the 3rd quarter valued at about $12,496,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.